HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma

SIMPLE SUMMARY: The major obstacle for the long-term success of targeted therapies in melanoma is the occurrence of resistance. Here, we present a new mechanism of targeted therapy resistance in melanoma where the treatment with the BRAF inhibitor vemurafenib causes an increased activation of HER3 v...

Descripción completa

Detalles Bibliográficos
Autores principales: Hüser, Laura, Kokkaleniou, Marianthi-Maria, Granados, Karol, Dworacek, Jennifer, Federico, Aniello, Vierthaler, Marlene, Novak, Daniel, Arkhypov, Ihor, Hielscher, Thomas, Umansky, Viktor, Altevogt, Peter, Utikal, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764938/
https://www.ncbi.nlm.nih.gov/pubmed/33327495
http://dx.doi.org/10.3390/cancers12123761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764938/
https://www.ncbi.nlm.nih.gov/pubmed/33327495
http://dx.doi.org/10.3390/cancers12123761

Ejemplares similares